Cargando…

Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial

Alzheimer's disease (AD) is associated with cognitive dysfunction. Evidence indicates that gut microbiota is altered in the AD and, hence, modifying the gut flora may affect the disease. In the previous clinical research we evaluated the effect of a probiotic combination on the cognitive abilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Agahi, Azadeh, Hamidi, Gholam Ali, Daneshvar, Reza, Hamdieh, Mostafa, Soheili, Masoud, Alinaghipour, Azam, Esmaeili Taba, Seyyed Mohammad, Salami, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104449/
https://www.ncbi.nlm.nih.gov/pubmed/30158897
http://dx.doi.org/10.3389/fneur.2018.00662
_version_ 1783349490162335744
author Agahi, Azadeh
Hamidi, Gholam Ali
Daneshvar, Reza
Hamdieh, Mostafa
Soheili, Masoud
Alinaghipour, Azam
Esmaeili Taba, Seyyed Mohammad
Salami, Mahmoud
author_facet Agahi, Azadeh
Hamidi, Gholam Ali
Daneshvar, Reza
Hamdieh, Mostafa
Soheili, Masoud
Alinaghipour, Azam
Esmaeili Taba, Seyyed Mohammad
Salami, Mahmoud
author_sort Agahi, Azadeh
collection PubMed
description Alzheimer's disease (AD) is associated with cognitive dysfunction. Evidence indicates that gut microbiota is altered in the AD and, hence, modifying the gut flora may affect the disease. In the previous clinical research we evaluated the effect of a probiotic combination on the cognitive abilities of AD patients. Since, in addition to pathological disorders, the AD is associated with changes in oxidant/antioxidant and inflammatory/anti-inflammatory biomarkers, the present work was designed to evaluate responsiveness of the inflammatory and oxidative biomarkers to the probiotic treatment. The control (CON) and probiotic (PRO) AD patients were treated for 12 weeks by the placebo and probiotic supplementation, respectively. The patients were cognitively assessed by Test Your Memory (TYM = 50 scores). Also serum concentrations of nitric oxide (NO), glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde (MDA), 8-hydroxy-2′ -deoxyguanosine (8-OHdG) and cytokines (TNF-a, IL-6, and IL-10) were measured. The cognitive test and the serum biomarkers were assessed pre- and post-treatment. According to TYM test 83.5% of the patients showed severe AD. The CON (12.86% ± 8.33) and PRO (−9.35% ± 16.83) groups not differently scored the cognitive test. Not pronounced change percent was found in the serum level of TNF-α (1.67% ± 1.33 vs. −0.15% ± 0.27), IL-6 (0.35% ± 0.17 vs. 2.18% ± 0.15), IL-10 (0.05% ± 0.10 vs. −0.70% ± 0.73), TAC (0.07% ± 0.07 and −0.06% ± 0.03), GSH (0.08% ± 0.05 and 0.04% ± 0.03) NO (0.11% ± 0.06 and 0.05% ± 0.09), MDA (−0.11% ± 0.03 and −0.17% ± 0.03), 8-OHdG (43.25% ± 3.01 and 42.70% ± 3.27) in the CON and PRO groups, respectively. We concluded that the cognitive and biochemical indications in the patients with severe AD are insensitive to the probiotic supplementation. Therefore, in addition to formulation and dosage of probiotic bacteria, severity of disease and time of administration deeply affects results of treatment.
format Online
Article
Text
id pubmed-6104449
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61044492018-08-29 Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial Agahi, Azadeh Hamidi, Gholam Ali Daneshvar, Reza Hamdieh, Mostafa Soheili, Masoud Alinaghipour, Azam Esmaeili Taba, Seyyed Mohammad Salami, Mahmoud Front Neurol Neurology Alzheimer's disease (AD) is associated with cognitive dysfunction. Evidence indicates that gut microbiota is altered in the AD and, hence, modifying the gut flora may affect the disease. In the previous clinical research we evaluated the effect of a probiotic combination on the cognitive abilities of AD patients. Since, in addition to pathological disorders, the AD is associated with changes in oxidant/antioxidant and inflammatory/anti-inflammatory biomarkers, the present work was designed to evaluate responsiveness of the inflammatory and oxidative biomarkers to the probiotic treatment. The control (CON) and probiotic (PRO) AD patients were treated for 12 weeks by the placebo and probiotic supplementation, respectively. The patients were cognitively assessed by Test Your Memory (TYM = 50 scores). Also serum concentrations of nitric oxide (NO), glutathione (GSH), total antioxidant capacity (TAC), malondialdehyde (MDA), 8-hydroxy-2′ -deoxyguanosine (8-OHdG) and cytokines (TNF-a, IL-6, and IL-10) were measured. The cognitive test and the serum biomarkers were assessed pre- and post-treatment. According to TYM test 83.5% of the patients showed severe AD. The CON (12.86% ± 8.33) and PRO (−9.35% ± 16.83) groups not differently scored the cognitive test. Not pronounced change percent was found in the serum level of TNF-α (1.67% ± 1.33 vs. −0.15% ± 0.27), IL-6 (0.35% ± 0.17 vs. 2.18% ± 0.15), IL-10 (0.05% ± 0.10 vs. −0.70% ± 0.73), TAC (0.07% ± 0.07 and −0.06% ± 0.03), GSH (0.08% ± 0.05 and 0.04% ± 0.03) NO (0.11% ± 0.06 and 0.05% ± 0.09), MDA (−0.11% ± 0.03 and −0.17% ± 0.03), 8-OHdG (43.25% ± 3.01 and 42.70% ± 3.27) in the CON and PRO groups, respectively. We concluded that the cognitive and biochemical indications in the patients with severe AD are insensitive to the probiotic supplementation. Therefore, in addition to formulation and dosage of probiotic bacteria, severity of disease and time of administration deeply affects results of treatment. Frontiers Media S.A. 2018-08-15 /pmc/articles/PMC6104449/ /pubmed/30158897 http://dx.doi.org/10.3389/fneur.2018.00662 Text en Copyright © 2018 Agahi, Hamidi, Daneshvar, Hamdieh, Soheili, Alinaghipour, Esmaeili Taba and Salami. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Agahi, Azadeh
Hamidi, Gholam Ali
Daneshvar, Reza
Hamdieh, Mostafa
Soheili, Masoud
Alinaghipour, Azam
Esmaeili Taba, Seyyed Mohammad
Salami, Mahmoud
Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
title Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
title_full Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
title_fullStr Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
title_full_unstemmed Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
title_short Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
title_sort does severity of alzheimer's disease contribute to its responsiveness to modifying gut microbiota? a double blind clinical trial
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104449/
https://www.ncbi.nlm.nih.gov/pubmed/30158897
http://dx.doi.org/10.3389/fneur.2018.00662
work_keys_str_mv AT agahiazadeh doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT hamidigholamali doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT daneshvarreza doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT hamdiehmostafa doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT soheilimasoud doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT alinaghipourazam doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT esmaeilitabaseyyedmohammad doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial
AT salamimahmoud doesseverityofalzheimersdiseasecontributetoitsresponsivenesstomodifyinggutmicrobiotaadoubleblindclinicaltrial